# An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

> clinical trial · VERIFIED · 2026-08-18

Status: RECRUITING · Sponsor: Novartis Pharmaceuticals · Condition: Metastatic Hormone-sensitive Prostate Cancer

- Company: Novartis Pharmaceuticals
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06991556

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.